XOMA Royalty Corporation (XOMA)
| Market Cap | 451.61M +86.7% |
| Revenue (ttm) | 52.15M +83.1% |
| Net Income | 18.52M |
| EPS | 1.46 |
| Shares Out | 11.92M |
| PE Ratio | 26.03 |
| Forward PE | 34.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 89,647 |
| Open | 37.89 |
| Previous Close | 37.89 |
| Day's Range | 37.00 - 38.38 |
| 52-Week Range | 22.29 - 40.74 |
| Beta | 0.68 |
| Analysts | Strong Buy |
| Price Target | 67.00 (+76.97%) |
| Earnings Date | May 12, 2026 |
About XOMA
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for XOMA stock is "Strong Buy." The 12-month stock price target is $67.0, which is an increase of 76.97% from the latest price.
News
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Roy...
XOMA Royalty Jumps After Q4 Double Beat, Signals Pipeline Catalysts Ahead
XOMA Royalty Corporation (NASDAQ: XOMA) shares are trading higher Wednesday after the company reported fourth-quarter financial results.
XOMA Royalty Earnings Call Transcript: Q4 2025
2025 saw strong financial growth, with royalty receipts up 68% year-over-year and positive operating cash flow enabling $16 million in share buybacks. The portfolio expanded to over 120 assets, with s...
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
Portfolio receipts : • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties up ...
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results o...
XOMA Royalty Transcript: Leerink Global Healthcare Conference 2026
Management highlighted a diversified, royalty-driven portfolio strategy, recent creative acquisitions, and ongoing litigation with J&J over Tremfya royalties. Financials show strong cash flow and low ...
XOMA Royalty Transcript: TD Cowen 46th Annual Health Care Conference
The company has built a diversified royalty portfolio with over 120 assets, including 15 in phase III, and uses creative transactions to drive growth and tax efficiency. Key catalysts include multiple...
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helpin...
XOMA Royalty Announces CFO Transition
EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from his...
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previo...
Mural Oncology Announces Sanction of the Scheme by the High Court
WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”) announces that the High Court of Ireland has today sanctioned the scheme of arrangement betwee...
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) today announced it has successfully completed its previously announced acquisition of all...
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
Business development : Secures royalty economic interests in two early stage partnered assets through XOMA Royalty's announced expected acquisition of LAVA Therapeutics.
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
- Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Nether...
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V.
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October...
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
EMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helpi...
XOMA Royalty Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Management highlighted rapid portfolio expansion, increased cash flow, and a focus on early-stage, high-potential assets. Upcoming phase three data and new acquisitions are expected to drive further g...
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
EMERYVILLE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Inve...
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation ...
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
Business development : Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Ro...
HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Hille...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.
NEW YORK , Aug. 5, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by HilleVax, Inc. (NASDAQ: HLVX) and its board of directors concerning the proposed acquisi...
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V.
ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif.